NCT00791557

Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease

An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: University Hospitals Cleveland Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Subjects must be 18- 75 years old and have a history of both inflammatory bowels disease (Crohn's or ulcerative colitis) and pyoderma gangrenosum. This is a 6 month open label study of an intravenous (IV) medication. Visits occur every 2 weeks initially, then every 1-2 months later in the study.

Conditions

• Pyoderma Gangrenosum
• Crohn's Disease
• Ulcerative Colitis
• Inflammatory Bowel Disease

Interventions

Type	Name	Description
DRUG	Infliximab	IV drug given at weeks 1,2,14,22

Timeline

• Start date: 2008-10-01
• Primary completion: 2009-12-01
• Completion: 2010-02-01
• First posted: 2008-11-14
• Last updated: 2016-11-02
• Results posted: 2013-11-15

Locations

1 site across 1 country: United States